BRIEF-Humacyte Going Public Via Merger With Alpha Healthcare Acquisition Corp

Reuters2021-02-17

Feb 17 (Reuters) - Alpha Healthcare Acquisition Corp

:

* HUMACYTE, A TRANSFORMATIVE BIOTECHNOLOGY PLATFORM COMPANY CAPABLE OF MANUFACTURING UNIVERSALLY IMPLANTABLE BIOENGINEERED HUMAN TISSUE AT COMMERCIAL SCALE, GOING PUBLIC VIA MERGER WITH ALPHA HEALTHCARE ACQUISITION CORP.

* ALPHA HEALTHCARE ACQUISITION CORP - TRANSACTION VALUES HUMACYTE AT A PRE-MONEY VALUATION OF $800 MILLION

* ALPHA HEALTHCARE ACQUISITION CORP - FOLLOWING TRANSACTION CLOSING, HUMACYTE IS EXPECTED TO HAVE A MARKET CAPITALIZATION OF $1.1 BILLION

* ALPHA HEALTHCARE ACQUISITION CORP - TRANSACTION IS EXPECTED TO PROVIDE UP TO $255 MILLION OF CASH PROCEEDS, INCLUDING A FULLY COMMITTED $175 MILLION PIPE

* ALPHA HEALTHCARE ACQUISITION CORP - AS A RESULT OF OUTSIZED DEMAND, PIPE OFFERING WAS OVERSUBSCRIBED AND UPSIZED

* ALPHA HEALTHCARE ACQUISITION CORP - COMBINED COMPANY EXPECTED TO TRADE ON NASDAQ CAPITAL MARKET UNDER SYMBOL "HUMA."

* ALPHA HEALTHCARE ACQUISITION CORP - PIPE INCLUDED FRESENIUS MEDICAL CARE, ORBIMED, MONASHEE INVESTMENT MANAGEMENT, ALEXANDRIA VENTURE INVESTMENTS

* ALPHA HEALTHCARE ACQUISITION CORP - PIPE INCLUDED UBS O'CONNOR, MORGAN CREEK CAPITAL, AND A NUMBER OF UNNAMED HEALTH CARE FOCUSED FUNDS

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2112483776?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-02-17 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2112483776","market":"us","top_or_hot":-1,"title":"BRIEF-Humacyte Going Public Via Merger With Alpha Healthcare Acquisition Corp","media":"Reuters","content":"<html><body><p>Feb 17 (Reuters) - <a href=\"https://laohu8.com/S/AHAC\">Alpha Healthcare Acquisition Corp</a></p><p> :</p><p>   * HUMACYTE, A TRANSFORMATIVE BIOTECHNOLOGY PLATFORM COMPANY CAPABLE OF MANUFACTURING UNIVERSALLY IMPLANTABLE BIOENGINEERED HUMAN TISSUE AT COMMERCIAL SCALE, GOING PUBLIC VIA MERGER WITH ALPHA HEALTHCARE ACQUISITION CORP.</p><p>   * ALPHA HEALTHCARE ACQUISITION CORP - TRANSACTION VALUES HUMACYTE AT A PRE-MONEY VALUATION OF $800 MILLION</p><p>   * ALPHA HEALTHCARE ACQUISITION CORP - FOLLOWING TRANSACTION CLOSING, HUMACYTE IS EXPECTED TO HAVE A MARKET CAPITALIZATION OF $1.1 BILLION</p><p>   * ALPHA HEALTHCARE ACQUISITION CORP - TRANSACTION IS EXPECTED TO PROVIDE UP TO $255 MILLION OF CASH PROCEEDS, INCLUDING A FULLY COMMITTED $175 MILLION PIPE</p><p>   * ALPHA HEALTHCARE ACQUISITION CORP - AS A RESULT OF OUTSIZED DEMAND, PIPE OFFERING WAS OVERSUBSCRIBED AND UPSIZED</p><p>   * ALPHA HEALTHCARE ACQUISITION CORP - COMBINED COMPANY EXPECTED TO TRADE ON NASDAQ CAPITAL MARKET UNDER SYMBOL \"HUMA.\"</p><p>   * ALPHA HEALTHCARE ACQUISITION CORP - PIPE INCLUDED FRESENIUS MEDICAL CARE, ORBIMED, MONASHEE INVESTMENT MANAGEMENT, ALEXANDRIA VENTURE INVESTMENTS</p><p>   * ALPHA HEALTHCARE ACQUISITION CORP - PIPE INCLUDED UBS O'CONNOR, MORGAN CREEK CAPITAL, AND A NUMBER OF UNNAMED HEALTH CARE FOCUSED FUNDS</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Humacyte Going Public Via Merger With Alpha Healthcare Acquisition Corp</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Humacyte Going Public Via Merger With Alpha Healthcare Acquisition Corp\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-17 20:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Feb 17 (Reuters) - <a href=\"https://laohu8.com/S/AHAC\">Alpha Healthcare Acquisition Corp</a></p><p> :</p><p>   * HUMACYTE, A TRANSFORMATIVE BIOTECHNOLOGY PLATFORM COMPANY CAPABLE OF MANUFACTURING UNIVERSALLY IMPLANTABLE BIOENGINEERED HUMAN TISSUE AT COMMERCIAL SCALE, GOING PUBLIC VIA MERGER WITH ALPHA HEALTHCARE ACQUISITION CORP.</p><p>   * ALPHA HEALTHCARE ACQUISITION CORP - TRANSACTION VALUES HUMACYTE AT A PRE-MONEY VALUATION OF $800 MILLION</p><p>   * ALPHA HEALTHCARE ACQUISITION CORP - FOLLOWING TRANSACTION CLOSING, HUMACYTE IS EXPECTED TO HAVE A MARKET CAPITALIZATION OF $1.1 BILLION</p><p>   * ALPHA HEALTHCARE ACQUISITION CORP - TRANSACTION IS EXPECTED TO PROVIDE UP TO $255 MILLION OF CASH PROCEEDS, INCLUDING A FULLY COMMITTED $175 MILLION PIPE</p><p>   * ALPHA HEALTHCARE ACQUISITION CORP - AS A RESULT OF OUTSIZED DEMAND, PIPE OFFERING WAS OVERSUBSCRIBED AND UPSIZED</p><p>   * ALPHA HEALTHCARE ACQUISITION CORP - COMBINED COMPANY EXPECTED TO TRADE ON NASDAQ CAPITAL MARKET UNDER SYMBOL \"HUMA.\"</p><p>   * ALPHA HEALTHCARE ACQUISITION CORP - PIPE INCLUDED FRESENIUS MEDICAL CARE, ORBIMED, MONASHEE INVESTMENT MANAGEMENT, ALEXANDRIA VENTURE INVESTMENTS</p><p>   * ALPHA HEALTHCARE ACQUISITION CORP - PIPE INCLUDED UBS O'CONNOR, MORGAN CREEK CAPITAL, AND A NUMBER OF UNNAMED HEALTH CARE FOCUSED FUNDS</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AHACU","symbol_name":"Alpha Healthcare Acquisition Corp.","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2112483776","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2112483776","pubTimestamp":1613565423,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Feb 17 (Reuters) - Alpha Healthcare Acquisition Corp :   * HUMACYTE, A TRANSFORMATIVE BIOTECHNOLOGY ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AHACU":"Alpha Healthcare Acquisition Corp."},"translate_title":"Humacyte与Alpha Healthcare Acquisition公司合并上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AHAC":1,"AHACW":1,"AHACU":1},"content_text":"Feb 17 (Reuters) - Alpha Healthcare Acquisition Corp :   * HUMACYTE, A TRANSFORMATIVE BIOTECHNOLOGY PLATFORM COMPANY CAPABLE OF MANUFACTURING UNIVERSALLY IMPLANTABLE BIOENGINEERED HUMAN TISSUE AT COMMERCIAL SCALE, GOING PUBLIC VIA MERGER WITH ALPHA HEALTHCARE ACQUISITION CORP.   * ALPHA HEALTHCARE ACQUISITION CORP - TRANSACTION VALUES HUMACYTE AT A PRE-MONEY VALUATION OF $800 MILLION   * ALPHA HEALTHCARE ACQUISITION CORP - FOLLOWING TRANSACTION CLOSING, HUMACYTE IS EXPECTED TO HAVE A MARKET CAPITALIZATION OF $1.1 BILLION   * ALPHA HEALTHCARE ACQUISITION CORP - TRANSACTION IS EXPECTED TO PROVIDE UP TO $255 MILLION OF CASH PROCEEDS, INCLUDING A FULLY COMMITTED $175 MILLION PIPE   * ALPHA HEALTHCARE ACQUISITION CORP - AS A RESULT OF OUTSIZED DEMAND, PIPE OFFERING WAS OVERSUBSCRIBED AND UPSIZED   * ALPHA HEALTHCARE ACQUISITION CORP - COMBINED COMPANY EXPECTED TO TRADE ON NASDAQ CAPITAL MARKET UNDER SYMBOL \"HUMA.\"   * ALPHA HEALTHCARE ACQUISITION CORP - PIPE INCLUDED FRESENIUS MEDICAL CARE, ORBIMED, MONASHEE INVESTMENT MANAGEMENT, ALEXANDRIA VENTURE INVESTMENTS   * ALPHA HEALTHCARE ACQUISITION CORP - PIPE INCLUDED UBS O'CONNOR, MORGAN CREEK CAPITAL, AND A NUMBER OF UNNAMED HEALTH CARE FOCUSED FUNDSSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2112483776","isCrawlerRequest":true}